Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport

肝X受体 胆固醇逆向转运 胆固醇 化学 药理学 低密度脂蛋白受体 高甘油三酯血症 脂蛋白 兴奋剂 ABCA1 载脂蛋白E 极低密度脂蛋白 受体 清道夫受体 内科学 内分泌学 载脂蛋白B 低密度脂蛋白 生物化学 生物 运输机 医学 核受体 甘油三酯 基因 转录因子 疾病
作者
Wenmin Yuan,Bilian Yu,Minzhi Yu,Rui Kuai,Emily E. Morin,Huilun Helen Wang,Die Hu,Jifeng Zhang,James Jaehyun Moon,Yanxing Chen,Yanhong Guo,Anna A. Schwendeman
出处
期刊:Journal of Controlled Release [Elsevier BV]
卷期号:329: 361-371 被引量:47
标识
DOI:10.1016/j.jconrel.2020.11.016
摘要

Liver X nuclear receptor (LXR) agonists are promising anti-atherosclerotic agents that increase the expression of cholesterol transporters on atheroma macrophages leading to increased efflux of cholesterol to endogenous high-density lipoprotein (HDL) acceptors. HDL subsequently delivers effluxed cholesterol to the liver by the process of reverse cholesterol transport, resulting in reduction of atherosclerotic plaques. However, LXR agonists administration triggers undesirable liver steatosis and hypertriglyceridemia due to increased fatty acid and sterol synthesis. LXR-induced liver toxicity, poor drug aqueous solubility and low levels of endogenous HDL acceptors in target patient populations limit the clinical translation of LXR agonists. Here, we propose a dual-antiatherogenic strategy for administration of the LXR agonist, T0901317 (T1317), by encapsulating in synthetic HDL (sHDL) nanoparticles. sHDL had been clinically proven to serve as cholesterol acceptors, resulting in plaque reduction in atherosclerosis patients. In addition, the hydrophobic core and endogenous atheroma-targeting ability of sHDL allow for encapsulation of water-insoluble drugs and their subsequent delivery to atheroma. Several compositions of sHDL were tested to optimize both T1317 encapsulation efficiency and ability of T1317-sHDL to efflux cholesterol. Optimized T1317-sHDL exhibited more efficient cholesterol efflux from macrophages and enhanced atheroma-targeting relative to free drug. Most importantly, in an apolipoprotein E deficient (ApoE-/-) atherosclerosis progression murine model, T1317-sHDL showed superior inhibition of atherogenesis and reduced hypertriglyceridemia side effects in comparison to the free drug and blank sHDL. The T1317-sHDL pharmacological efficacy was observed at doses lower than those previously described for LXR agents, which may have additional safety benefits. In addition, the established clinical manufacturing, safety and efficacy of blank sHDL nanoparticles used in this study could facilitate future clinical translation of LXR-loaded sHDLs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
隐形曼青的应助被千里洛采纳,获得10
刚刚
Zoey完成签到,获得积分10
1秒前
2秒前
三国时代发布了新的文献求助10
3秒前
4秒前
5秒前
小张医生完成签到,获得积分10
5秒前
6秒前
Jazz33333333完成签到,获得积分10
6秒前
CoCo发布了新的文献求助10
6秒前
6秒前
所所的应助被Zoey采纳,获得10
7秒前
endlessloop发布了新的文献求助10
9秒前
8R60d8的应助被dingo采纳,获得10
9秒前
李健的应助被合适忆枫采纳,获得20
9秒前
10秒前
欣慰的疾完成签到,获得积分20
10秒前
淡然冬灵发布了新的文献求助10
10秒前
JamesPei的应助被白日梦采纳,获得10
12秒前
12秒前
13秒前
风吹麦浪的应助被奋斗断秋采纳,获得10
14秒前
14秒前
endlessloop完成签到,获得积分10
14秒前
Jerry发布了新的文献求助10
15秒前
和谐的数据线完成签到 ,获得积分10
15秒前
16秒前
科研通AI6.3的应助被小陈采纳,获得10
16秒前
欣慰的疾发布了新的文献求助10
17秒前
18秒前
youbei发布了新的文献求助10
19秒前
千里洛发布了新的文献求助10
19秒前
共享精神的应助被美丽采纳,获得10
19秒前
科研通AI6.3的应助被眼药水采纳,获得10
21秒前
大个的应助被开心德地采纳,获得10
21秒前
21秒前
GFFino完成签到 ,获得积分10
21秒前
22秒前
丘比特的应助被单薄傲易采纳,获得30
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189137
求助须知:如何正确求助?哪些是违规求助? 9576601
关于积分的说明 21848766
捐赠科研通 7787145
什么是DOI,文献DOI怎么找? 3435490
关于科研通互助平台的介绍 2559732
邀请新用户注册赠送积分活动 2482462